Prolia (Denosumab) Cost in Maine: Prices, Insurance, and Savings in 2026

Denosumab, marketed as Prolia, works by binding to and inhibiting RANKL, a key regulator of the bone resorption process. The standard Prolia dosing regimen consists of 60 mg administered subcutaneously twice yearly; FDA approval covers its use in postmenopausal osteoporosis, hormone therapy-related bone loss, glucocorticoid-induced osteoporosis, and high-risk male osteoporosis. Xgeva, another denosumab formulation dosed at 120 mg, addresses skeletal complications in cancer patients but operates under distinct pricing and regulatory pathways and is outside the scope of this article.

The real cost question for a Maine patient is usually not "what does Prolia cost" in the abstract, but which of three payment paths applies: Medicare Part B, MaineCare or commercial insurance, or uninsured cash pay. Those three paths produce out-of-pocket costs that differ by hundreds to thousands of dollars per year, far more than any variation caused by which pharmacy or clinic in Maine administers the injection.

Evidence anchor: Prolia's clinical benefit for fracture reduction is established by the placebo-controlled FREEDOM trial in postmenopausal women with osteoporosis, and stopping denosumab without a follow-up antiresorptive plan is associated with rebound vertebral fracture risk in post-hoc analysis of that trial's extension data. Cost and coverage details below (list price, copay amounts, prior authorization rules) are separate from that clinical evidence base and change over time; they should be confirmed with your insurer, MaineCare, or the prescribing clinic before you rely on a specific dollar figure.

What Prolia costs before insurance

Amgen sets a wholesale acquisition cost for a single 60 mg Prolia syringe that has been widely reported in the low four figures per dose, meaning a full cash-pay year (two doses) runs into the thousands of dollars. We are not able to verify an exact current cash price from the primary sources available for this page, and list prices change. If you are paying cash, ask the dispensing pharmacy or infusion clinic for their current billed price rather than relying on any published figure, including this one.

As of mid-2026, no interchangeable denosumab biosimilar has launched in the United States. Checking the FDA's current product information for Prolia is the recommended way to confirm any change in that status. Because there is no biosimilar competition yet, cash-pay pricing has little downward pressure and is expected to be broadly similar across states, including Maine, since Amgen sets a single national list price. Local pharmacy markups and dispensing fees can shift the number modestly, but they do not explain large price differences between states.

MaineCare (Medicaid) coverage

MaineCare covers Prolia for its FDA-approved osteoporosis indications, but coverage of biologic injectables through Medicaid programs generally requires prior authorization, and MaineCare's specific criteria (bone density thresholds, documented failure of oral bisphosphonates, fracture history) can change. We could not verify MaineCare's current prior authorization criteria or turnaround times from the source material for this page. Before assuming a specific rule applies to you, ask your prescriber's office to check MaineCare's current preferred drug list and prior authorization policy for denosumab, or contact MaineCare member services directly.

Injectable biologics like Prolia are typically billed under the medical benefit rather than the pharmacy benefit, since the drug is purchased and administered by the clinic ("buy and bill") rather than dispensed at a retail pharmacy counter. This billing structure is standard for physician-administered injectables generally; confirm with your specific clinic how they bill MaineCare for this drug.

Commercial insurance in Maine

Most commercial insurers covering Maine members include denosumab on formulary for its approved indications, again through the medical benefit. Typical cost-sharing structures for specialty injectables include coinsurance (a percentage of the drug's cost) or a flat copay per administration, and patients on high-deductible health plans may owe the full negotiated price until the deductible is met. Exact percentages, copay amounts, and step-therapy requirements vary by plan and change from year to year, so a specific number quoted for one plan should not be assumed to apply to another.

Many commercial plans require a documented trial of, or contraindication to, a generic oral bisphosphonate (such as alendronate) before approving denosumab. If your plan denies coverage, an appeal that documents bisphosphonate intolerance or contraindication, along with bone density and fracture history, is the standard path to review. The FREEDOM trial, which enrolled 7,868 postmenopausal women with osteoporosis and found that denosumab reduced new vertebral, hip, and nonvertebral fractures compared to placebo over three years, is the primary trial evidence supporting denosumab's use and can be cited in appeal letters (FREEDOM trial, PubMed). Ask your plan directly for its current specialty drug cost-sharing schedule rather than relying on a generalized estimate.

Medicare coverage

Original Medicare Part B covers Prolia as a physician-administered drug, and Part B generally requires a 20% coinsurance after the annual Part B deductible is met. The exact deductible and resulting coinsurance dollar amount change annually and should be checked against Medicare's current published rates rather than a prior year's figure. Medicare Advantage plans sold in Maine must cover Part B drugs at least as generously as Original Medicare, but they set their own prior authorization rules and cost-sharing, so plan-to-plan variation is expected. Call your specific Medicare Advantage plan before your appointment to confirm what you will owe.

Part D's annual out-of-pocket cap on prescription drugs does not generally apply to Prolia, because the drug is usually billed under the Part B medical benefit rather than dispensed through a Part D pharmacy benefit. This distinction matters because patients sometimes assume the Part D cap protects them for injectables billed as a medical benefit; it typically does not.

Manufacturer copay assistance

Amgen has historically offered a commercial copay assistance program (marketed as FIRST STEP) for patients with private or commercial insurance. These programs typically exclude patients enrolled in Medicare, Medicaid, or other government insurance, and the maximum annual benefit and enrollment process can change from year to year. Confirm current eligibility rules, benefit caps, and enrollment steps directly with Amgen's patient support line or the program's official page before assuming a specific dollar benefit applies, since manufacturer copay program terms are revised periodically and are not something this page can verify as current.

Amgen has also historically operated a patient assistance foundation for uninsured or low-income patients who meet income eligibility thresholds. Income cutoffs, documentation requirements, and processing times for these programs change and should be confirmed directly with the program rather than assumed from a general description.

Compounded denosumab: what is and is not established

Federal law under Section 503A of the Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare patient-specific medications, including biologics, under an individual prescription, provided they meet state licensing and sterile compounding standards (FDA, Section 503A). This legal framework applies nationally, including in Maine, but it does not mean every compounding pharmacy compounds monoclonal antibody biologics, and availability varies.

What is not established: the FDA does not verify the safety, potency, purity, or bioequivalence of compounded biologic products the way it does for an FDA-approved drug. There is no clinical trial evidence comparing compounded denosumab to branded Prolia. A patient considering this route should understand that potential cost savings come with a real trade-off in manufacturing oversight, and should discuss the risk-benefit balance with their prescriber before switching from an FDA-approved product.

Telehealth prescribing

Clinicians can evaluate a patient by telehealth, review bone density results and labs, and issue a prescription for denosumab. The injection itself must still be given in person by a healthcare professional, since it is a subcutaneous injection, not an oral or self-administered product. State-specific telehealth prescribing rules can change, so confirm current requirements with the prescribing practice rather than assuming a blanket policy.

Why cost matters clinically, not just financially

Denosumab's effect on bone depends on staying on schedule. A post-hoc analysis of the FREEDOM trial and its extension has been reported to find that vertebral fracture rates rose substantially in the year after patients stopped denosumab, compared to fracture rates during active treatment. This is why guideline bodies, including the Endocrine Society, generally recommend planning a transition to another antiresorptive agent, typically a bisphosphonate, before or at the time denosumab is discontinued, rather than stopping abruptly (Endocrine Society osteoporosis guidelines). A cost barrier that causes a missed or delayed dose is not a neutral inconvenience; it is a clinical event worth discussing with your prescriber, including whether bridging therapy is needed if an injection will be significantly delayed.

What is established, what is plausible, and what is not established

Established: Denosumab 60 mg every six months reduces vertebral, hip, and nonvertebral fracture risk in postmenopausal women with osteoporosis compared to placebo, based on randomized trial evidence. Stopping denosumab is associated with a rebound increase in vertebral fracture risk in trial follow-up data. Section 503A compounding of patient-specific prescriptions, including biologics, is legally permitted under federal law when state licensing and sterile compounding standards are met.

Plausible but not confirmed for this page: Specific cash prices, MaineCare prior authorization timelines, exact commercial copay ranges, and the current Amgen copay card benefit cap. These figures are commonly cited in patient materials but change over time and were not independently verified against a current primary source for this draft.

Not established: That compounded denosumab is bioequivalent or clinically interchangeable with branded Prolia. That any specific dollar savings can be guaranteed to a Maine patient through a particular program without direct confirmation from that program.

Verification checklist: stable facts vs. facts you must confirm yourself

Use this to separate what is unlikely to change soon from what changes often and needs a direct check before you make a financial decision.

Stable, federally or clinically anchored (safe to treat as current without re-checking each time):

• Denosumab's FDA-approved indications (postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, bone loss with certain hormone therapies, male osteoporosis)
• The 60 mg every-six-month dosing schedule for Prolia (distinct from Xgeva's 120 mg oncology dosing)
• FREEDOM trial fracture-reduction evidence and the rebound fracture risk after discontinuation
• The legal basis for 503A compounding under federal law
• Guideline recommendation to plan a transition therapy before stopping denosumab

Date-sensitive, verify before relying on it (check within days of your decision, not once a year):

• Amgen's current wholesale/cash price for a Prolia syringe
• Whether a denosumab biosimilar has launched or received FDA approval
• MaineCare's current prior authorization criteria and required documentation
• Your specific commercial or Medicare Advantage plan's copay, coinsurance, or step-therapy rules for this drug
• The current Amgen copay assistance program's eligibility rules and maximum annual benefit
• Income eligibility thresholds and application requirements for any manufacturer patient assistance program
• Whether a specific 503A pharmacy near you currently compounds denosumab

Who to call for each date-sensitive item: your insurer's member services line (plan-specific cost-sharing), MaineCare member services (Medicaid rules), the prescribing clinic's billing office (cash price and 340B eligibility if applicable), and Amgen's patient support line (copay card and foundation assistance terms).

Common questions

Does MaineCare cover Prolia? Yes, for FDA-approved osteoporosis indications, generally with prior authorization. The specific documentation MaineCare requires can change, so confirm current criteria with your prescriber's office or MaineCare directly rather than relying on a generic description.

Is compounded denosumab legal in Maine? A licensed 503A compounding pharmacy can legally prepare a patient-specific denosumab formulation under federal law, provided it meets state licensing and sterile compounding requirements. This does not mean the compounded product has been shown to be bioequivalent to branded Prolia, since the FDA does not verify that for compounded biologics.

What happens if I miss a dose because of cost? Delaying or stopping denosumab without a bridging plan is associated with a rebound increase in vertebral fracture risk based on post-hoc trial data. If cost is likely to delay your next injection, tell your prescriber before the delay happens so a bridging strategy, such as a bisphosphonate, can be considered.

Will a biosimilar make Prolia cheaper? As of mid-2026 no interchangeable denosumab biosimilar has launched in the United States. If one launches, price competition would be expected to eventually lower costs, based on the pattern seen with other biologic classes, but no specific percentage reduction can be predicted with confidence at this time. Check the FDA's Prolia page for the current biosimilar landscape.

Should I choose based on price alone? No. Cost matters because missed doses carry real fracture risk, but switching products, delaying treatment, or pursuing a compounded alternative should be discussed with your prescriber as a clinical decision with financial constraints factored in, not a financial decision made independently of clinical input.

When to seek urgent care

New or worsening back pain after starting or stopping denosumab, a fall or sudden fracture, or signs of a severe allergic reaction to the injection (facial swelling, difficulty breathing, widespread rash) warrant urgent medical evaluation rather than waiting for a routine follow-up appointment.

References

2. FDA. Section 503A of the Federal Food, Drug, and Cosmetic Act: human drug compounding. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
3. Endocrine Society. Clinical practice guidelines: osteoporosis. https://www.endocrine.org/clinical-practice-guidelines/osteoporosis
4. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (FREEDOM trial). PubMed. https://pubmed.ncbi.nlm.nih.gov/19671655/
5. FDA. Prolia approval history and application information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125320

This article is drafted for editorial and qualified medical review and has not yet received that review. It does not provide individualized dosing or coverage advice. Cost, coverage, and program details are date-sensitive; confirm current figures with your insurer, MaineCare, and the manufacturer before making a treatment or financial decision.